Enzastaurin
- Generic Name
- Enzastaurin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H29N5O2
- CAS Number
- 170364-57-5
- Unique Ingredient Identifier
- UC96G28EQF
- Background
Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
- Indication
Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2
- Registration Number
- NCT00536939
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT00533429
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States
Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 160
- Registration Number
- NCT00530621
- Locations
- 🇵🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto, Portugal
A Study of Enzastaurin in Participants With Follicular Lymphoma
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT00475644
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 108
- Registration Number
- NCT00466440
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Sisto, Italy
A Study of Enzastaurin in Patients With Leukemia
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2009-03-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT00452257
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 65
- Registration Number
- NCT00452413
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, United States
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
- Conditions
- Interventions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 101
- Registration Number
- NCT00451178
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Crosse, Wisconsin, United States
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 156
- Registration Number
- NCT00451555
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
Chemotherapy for Participants With Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT00436280
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.